Showing 8771-8780 of 18119 results for "".
- The Role of IncC Plasmids in Antimicrobial Resistance: Implications from the Genomic Study of Providencia stuartiihttps://reachmd.com/news/incc-plasmids-antimicrobial-resistance/2484816/NDM-1 producing Providencia stuartii isolates were identified carrying plasmid-driven carbapenemase determinants that sharply narrow therapeutic options in hospitalized patients. Whole-g
- Combined Ianalumab and Eltrombopag Therapy in Immune Thrombocytopenia: Insights from the VAYHIT2 Trialhttps://reachmd.com/news/combined-ianalumab-and-eltrombopag-therapy-in-immune-thrombocytopenia-insights-from-the-vayhit2-trial/2484822/VAYHIT2: Ianalumab plus eltrombopag extends response durability in previously treated p
- Intraoperative Predictors and Management of Pituitary Dysfunction Post-Surgeryhttps://reachmd.com/news/intraoperative-predictors-pituitary-dysfunction-post-surgery/2484812/In adults undergoing transsphenoidal surgery for non‑functioning pituitary adenomas, relative intraoperative hypotension and early postoperative rises in brain‑injury biomark
- Robotic vs. Laparoscopic Roux-en-Y Gastric Bypass: Insights from the MBSAQIP Databasehttps://reachmd.com/news/robotic-laparoscopic-roux-en-y-gastric-bypass/2484817/A Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (2020–2023) registry analysis shows equivalent 30-day complication rates for robotic and lapar
- FDA Regulatory Moves and Their Impact on Urologic Therapeautics: A Case of Detalimogenehttps://reachmd.com/news/fda-regulatory-moves-and-their-impact-on-urologic-therapeautics-a-case-of-detalimogene/2484820/The FDA selected detalimogene for its Manufacturing Readiness Program, advancing regulatory alignment for this non
- Systematic Review Shows BTX Effective for Ischemic Digital Complicationshttps://reachmd.com/news/systematic-review-btx-effective-for-ischemic-digital-complications/2484841/Botulinum toxin (BTX) injections may offer a promising rescue therapy for patients with refractory digital ischemia, ulcers, or gangrene associated with systemic sclerosis and other vasculopathies, according to findings from a systematic review in
- Real-World Study Confirms Ixekizumab Outperforms Ustekinumab in Psoriasishttps://reachmd.com/news/real-world-study-confirms-ixekizumab-outperforms-ustekinumab-in-psoriasis/2484790/A recent real-world studyreplicated the results of the IXORA-S trial, which demonstrated the efficacy of ixekizumab over ustekinumab for treating moderate-to-severe plaque psoriasis. Researchers for the observational analysis, c
- Real-World Insights: Switching from Eculizumab to Ravulizumab in Paroxysmal Nocturnal Hemoglobinuriahttps://reachmd.com/news/real-world-insights-switching-from-eculizumab-to-ravulizumab-in-paroxysmal-nocturnal-hemoglobinuria/2484745/Switching adults with PNH from eculizumab to ravulizumab preserved biochemical and clinical disease control while substantially extending dosing intervals, according to
- Preclinical Advances in Sensitizing ER-Positive Breast Cancer to Immunotherapyhttps://reachmd.com/news/preclinical-advances-in-sensitizing-er-positive-breast-cancer-to-immunotherapy/2484775/Researchers at the Hospital del Mar Research Institute report a preclinical strategy that may sensitize ER-positive tumors to immune checkpoint blockade by combining est
- Navigating the Impact of the Newly Approved Dengue Vaccine in Brazilhttps://reachmd.com/news/navigating-the-impact-of-the-newly-approved-dengue-vaccine-in-brazil/2484785/Butantan-TV dengue vaccine has been licensed in Brazil as a single-dose immunization, enabling immediate incorporation into routine programs. A one-dose regimen sh